Show simple item record

dc.contributor.authorArmand, P.
dc.contributor.authorZinzani, P. L. L.
dc.contributor.authorLee, H. J.
dc.contributor.authorJohnson, N.
dc.contributor.authorBrice, P.
dc.contributor.authorRadford, John A
dc.contributor.authorRibrag, V.
dc.contributor.authorMolin, D.
dc.contributor.authorVassilakopoulos, T. P.
dc.contributor.authorTomita, A.
dc.contributor.authorvon Tresckow, B.
dc.contributor.authorShipp, M. A.
dc.contributor.authorHerrera, A. F.
dc.contributor.authorLin, J. X.
dc.contributor.authorKim, E.
dc.contributor.authorChakraborty, S.
dc.contributor.authorMarinello, P.
dc.contributor.authorMoskowitz, C. H.
dc.date.accessioned2022-10-19T13:13:19Z
dc.date.available2022-10-19T13:13:19Z
dc.date.issued2021en
dc.identifier.citationArmand P, Zinzani PLL, Lee HJ, Johnson N, Brice P, Radford J, et al. Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL). Blood. 2021 Nov;138. PubMed PMID: WOS:000736398805094.en
dc.identifier.doi10.1182/blood-2021-147881en
dc.identifier.urihttp://hdl.handle.net/10541/625638
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1182/blood-2021-147881en
dc.titleFive-year follow-up of keynote-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma (R/R cHL)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDana-Farber Cancer Institute, Boston, MAen
dc.identifier.journalBlooden
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record